Chemours Co (CC) Form 8-K — Aug 4, 2026

$CCForm 8-KItems 2.02, 9.01Filed Aug 4, 2026, 4:33 PM ET0001627223-26-000021Original filing

Chemours reported second quarter 2026 net sales of $1.6 billion, down about 1% year over year, and a net loss attributable to Chemours of $274 million, or $1.81 per diluted share, versus a $380 million loss in the prior-year quarter. The loss was driven by $225 million of litigation-related charges and $144 million of environmental charges tied to the newly announced EPA and WVDEP consent decree, partially offset by a $273 million gain on the Kuan Yin property sale. On an adjusted basis, Adjusted EBITDA came in at $247 million versus $260 million a year ago and Adjusted EPS was $0.42 versus $0.61, which management characterized as near the high end of the guidance range.

Key figures

Eps: -$1.81 per diluted share
Revenue: $1,591 million
Guidance: Q3 2026: Net Sales -5% to flat sequentially, Adjusted EBITDA $175-205 million, capex ~$65 million, FCF at least $50 million; FY2026: Net Sales +1-5%, Adjusted EBITDA $775-825 million, capex $250-280 million, FCF conversion above 25%, net leverage ~3.8x by year-end
Net Income: -$274 million (net loss attributable to Chemours)
Total Debt: $3.9 billion gross debt ($3,243 million net of cash)
Revenue Yoy: -1%
Total Assets: $7,150 million
Cash Position: $671 million unrestricted cash
Capex: $44 million
Adjusted eps: $0.42 vs $0.61 prior-year quarter
Fcf conversion: 46%
Free cash flow: $114 million vs $50 million prior-year quarter (+128%)
Adjusted ebitda: $247 million vs $260 million prior-year quarter
Total liquidity: $1.6 billion
Segment net sales: ["TSS $591 million (-1% YoY)","TT $661 million (+1% YoY)","APM $326 million (-6% YoY)"]
Term loan paydown: EUR 230 million of B-3 Euro-denominated Term Loan due August 2028
Net leverage ratio: 4.4x (vs 4.6x TTM prior)
Shares outstanding: 150463268
Adjusted net income: $64 million vs $91 million prior-year quarter
Operating cash flow: $158 million vs $93 million prior-year quarter
Environmental charges: $144 million
Segment adjusted ebitda: ["TSS $213 million (+3%)","TT $48 million (+2%)","APM $26 million (-48%)"]
Tio2 price increase ytd: approximately 5%
Litigation related charges: $225 million
Kuan yin property sale gain: $273 million

Price after filing

1 day: 0.0%7 days: -13.5%30 days: -8.4%

Close on the filing date to close N calendar days later (from $17.11). Historical, not a forecast.

AI analysis

Red flags7 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.